Complication | Treatment group | P value | |
No bevacizumab | bevacizumab | ||
Early postoperative period (within 1 month) | |||
Central retinal vein occlusion | 1 (1.8%) | 0 (0.0%) | NA |
Hypotonous maculopathy | 2 (3.6%) | 2 (3.8%) | 0.91 |
Choroidal effusion | 1 (1.8%) | 3 (5.8%) | 0.27 |
Hyphema | 2 (3.6%) | 1 (1.9%) | 0.58 |
Wound leak | 1 (1.8%) | 2 (3.8%) | 0.47 |
Late postoperative period (from 1 month to 12 months) | |||
Blebitis/endophthalmitis | 1 (1.8%) | 0 (0.0%) | NA |
Tenon’s cyst | 1 (1.8%) | 5 (9.6%) | 0.08 |
Microbial keratitis | 1 (1.8%) | 1 (1.9%) | 0.89 |
Corneal endothelial failure | 1 (1.8%) | 0 (0.0%) | NA |
Hypotonous maculopathy | 2 (3.6%) | 3 (5.8%) | 0.66 |
Although no vision threatening complications were observed within the bevacizumab group, one central retinal vein obstruction and one blebitis/endophthalmitis occurred in the control group. There were no differences in any non-vision-threatening complications between groups (table 3).